The largest database of trusted experimental protocols
> Living Beings > Population Group > Living Donors

Living Donors

Living donors are individuals who voluntarily provide organs or tissues for transplantation to another person.
This selfless act can save lives and improve the quality of life for recipients.
PubCompare.ai's innovative platform empowers living donor research by streamlining the process of identifying the best protocols from literature, preprints, and patents.
Its intuitive tools leverage AI-driven comparisons to help researchers easily locate and optimize the ideal protocols and products for their needs.
With PubCompare.ai, living donor research becomes more efficient and effective, ultimately contributing to advancements in this critical field of medicine.

Most cited protocols related to «Living Donors»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Anxiety Diabetes Mellitus Diagnosis Dialysis Donors Ethnicity Gender Generic Drugs Grafts Hypersensitivity Kidney Kidney Transplantation Living Donors Nurses Operative Surgical Procedures Pain Patients Population Group Range of Motion, Articular Reflex Transplant Recipients
The OPTN database of the United Network for Organ Sharing (UNOS) was used to identify patients registered on the waiting list on or before April 24, 2006, during 2 periods, pre-MELD (January 1, 1996–December 31, 2000) and post-MELD (February 28, 2002–March 31, 2006). The study population comprised all non-Hispanic black and non-Hispanic white patients aged 18 years or older who were liver transplant waiting list registrants during those periods. Race is identified by patients when registering on the UNOS waiting list. Hispanics were not included as the UNOS database has multiple variables that identify race and ethnicity with often discordant results.
Patients listed for retransplantation or multiorgan transplantation were excluded. Given the different criteria for organ allocation, patients were excluded if they were listed as status 1, defined as fulminant liver failure with a life expectancy without liver transplantation of less than 7 days. We also excluded patients listed as temporarily inactive because they could not be properly assessed for receipt of liver transplantation. The UNOS variables collected included listing date, age, sex, blood type, listing diagnoses, race, education level, insurance payer, UNOS region, calculated MELD score at listing and removal, waiting time, reason for removal from the waiting list, and comorbid illnesses. Waiting time was determined using the first date each patient was placed on the waiting list and the date of removal from the list.
Education level was grouped into 3 categories comprising no education or grade school education, high school and attended college without degree, and college degree or higher. The UNOS regions were grouped into 4 categories according to region of the country (northeast = UNOS regions 1, 2, and 9; southeast = UNOS regions 3, 4, and 11; midwest = UNOS regions 7, 8, and 10; and west = UNOS regions 5 and 6). Listing diagnoses were grouped into 11 common diagnostic categories including cryptogenic cirrhosis, hepatitis C virus, hepatitis B virus, Laennec cirrhosis, nonalcoholic steatohepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, alpha-1 antitrypsin deficiency, hemochromatosis, and HCC. All other diagnoses were combined into a category designated “other.”
Patients with reasons for removal from the waiting list, such as emergency transplant, died during transplant, and transplanted at another center, were combined into a category called “transplanted.” Similarly, patients removed from the waiting list with reasons such as medically unsuitable or too sick for liver transplantation were combined into a category called “too sick for liver transplantation,” and patients whose reasons for removal from the waiting list were identified as refused transplant, transferred to another center, other, condition improved, living donor, and removed in error were combined into a category called “other.” Patients who died before liver transplantation were kept as 1 category and called “died.”
Publication 2008
alpha 1-Antitrypsin Deficiency Autoimmune Chronic Hepatitis B virus, Hepatitis Cirrhosis, Cryptogenic Diagnosis Emergencies Ethnicity Hemochromatosis Hepatitis C virus Hispanics Liver Cirrhosis Liver Failure, Acute Liver Transplantations Living Donors Nonalcoholic Steatohepatitis Patients Primary Biliary Cholangitis Primary Sclerosing Cholangitis Transplantation
Patients presenting with suspected or known NAFLD who were undergoing a standard of care liver biopsy to diagnose and/or to assess the severity of the disease were enrolled in this study. All subjects were enrolled between 2012 and 2016 at a single tertiary care medical center. The study was approved by the institutional review board of Virginia Commonwealth University, and all subjects provided informed consent. All research was performed in accordance with the guidelines and regulations of the review board and the publisher. The liver biopsy was performed using a percutaneous approach or a transjugular approach in all instances. At the time of the biopsy, 1.5–2 cm core of tissue of 16 gauge diameter was sent for histological assessment and 2–5 mm of tissue was snap-frozen in liquid nitrogen at the bedside within five minutes of obtaining the biopsy. Those with biopsy-proven NAFLD were included for this analysis. Control subjects included those who had normal liver histology and did not have evidence of other common etiologies for liver disease such as hepatitis B and C, hemochromatosis, alcohol-associated liver disease. These subjects were either donors for living donor transplant or had a prior history of ALT fluctuations that was evaluated with a liver biopsy.
Full text: Click here
Publication 2019
Alcoholic Liver Diseases Biopsy Diagnosis Ethics Committees, Research Freezing Hemochromatosis Hepatitis B Liver Liver Diseases Living Donors Nitrogen Non-alcoholic Fatty Liver Disease Patients Tissues Transplant Donors
The respective iGeneTRAiN study designs and characteristics for subjects recruited with existing GWAS data are outlined in Table 1. In total, there are over 16494 recipients with 11669 donors across the 4 solid organs. The existing GWAS include participants with a wide geographic representation across the United States, The Netherlands, United Kingdom, Ireland, Spain, and Australia. The majority of transplant recipients in the studies are adults with the exception of 2 cohorts, which comprise approximately 1060 pediatric subjects. The study designs are primarily single or multisite prospective cohorts, and although a small number are retrospective in recruitment approach, most are continuing to accrue longitudinal transplant phenotypes and outcome events. Approximately 18900 samples were subjected to GWAS using a transplant-specific genomewide genotyping array (described below) and approximately 8600 additional samples genotyped using conventional GWAS arrays. The iGeneTRAiN studies range in size from less than 100 D-R pairs to several thousands of recipients. All kidney studies and 2 liver studies have varied proportions of living donor versus deceased donors. Of the 16494 recipients, approximately 81.3%, 12.1%, 1.7%, and 4% are of are of European, African, Asian, and Hispanic ancestry, respectively, with the remainder classified as “other,” and approximately 62% of D-R pairs have conventional 2- or 4-digit HLA typing available. Table S1 (SDC, http://links.lww.com/TP/B191) outlines information regarding specific clinical HLA typing performed, pretransplant anti-HLA immunization status, including peak panel-reactive antibody (PRA), and posttransplant recording of de novo anti-HLA antibodies across each of the 22 studies.
Publication 2015
Adult Anti-Antibodies Asian Americans Donors Europeans Fingers Genome-Wide Association Study Grafts Hispanics Immunization Immunoglobulins Kidney Liver Function Tests Living Donors Negroid Races Phenotype Transplant Recipients
The matched nondonor population was drawn from the Third National Health and Nutrition Examination Survey (NHANES III). In this cohort, medical information was obtained from patient self-report, physical examination, and radiologic and laboratory test results at NHANES III enrollment between 1988 and 1994. A healthy, screened nondonor population was derived from adult NHANES III participants by excluding those with identified contraindications to kidney transplantation (eAppendix 1 in the Supplement). Nondonors were individually matched with replacement to live donors using iterative expanding radius matching.6 (link),17 (link)-20 (link) Matching was based on age, sex, self-identified race, educational background, body mass index (BMI), smoking history, and systolic blood pressure (eAppendix 2 in the Supplement). Similar to the process outlined above for live donors, ESRD outcomes were ascertained by linkage to the CMS medical evidence Form 2728 and to the CMS patient profile and death notification Form 2746 (including records through September 30, 2008).
Publication 2014
Adult Dietary Supplements Index, Body Mass Kidney Failure, Chronic Kidney Transplantation Living Donors Patients Physical Examination Radius Systolic Pressure

Most recents protocols related to «Living Donors»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
American Indian or Alaska Native Biopsy Diabetes Mellitus Digestive System Ethics Committees, Research Gene Chips Gene Expression Genome, Human Genotype Kidney Kidney Diseases Kidney Glomerulus Living Donors Microarray Analysis Microdissection Tissue Procurement Tissues Vulnerable Populations
We will include all kidney transplant recipients from 2008 onwards that were prospectively enrolled by the STCS and gave informed consent. Exclusion criteria is living-donor transplantation. Multi-organ transplantation, pediatric patients, and pre-emptive transplantations may be considered for exclusion if there were not enough samples and events in these subpopulations (see also “Sensitivity analyses”).
Full text: Click here
Publication 2023
Hypersensitivity Kidney Transplantation Living Donors Organ Transplantation Patients Population Group Transplantation
From June-September 2020, ten professors (five pediatricians and five surgeons) in the Pediatric Committee of the Korea Society of Transplantation created and critically assessed the survey questionnaires and methods. The Institutional Review Board of Seoul National University Hospitalapproved the study protocol (IRB No. 2101-178-1193). Between 1 October and 30 November 2020, the cross-sectional ramdom survey was conducted using a Google form.
The survey link was referred by email to eleven National Universities, ten medical societies, the Korean Bar Association, and three high schools. Data of respondents’ characteristics and responses were collected.
Minors were defined as persons younger than 19 years according to the Korean national regulation. The survey included a structured set of 27 questions. Korean and English-translated versions of the questionnaire were added as Supplementary documents 1 and 2.
The questionnaire was divided into three stages, as shown in Figure 2:

(1) Pre-survey stage: Respondents’ basic attitudes (Question 1) toward minors’ organ donation were investigated prior to the main survey.

(2) Survey stage

(1) Respondents’ characteristics and basic knowledge: The survey stage entails the collection of respondents’ demographic data (Questions 2–8) and investigates their basic knowledge of organ transplantation and minors’ organ donation (Questions 9–10). The purpose of questions 25–26 was to examine respondents’ expectations of the minimum age at which individuals can donate their organs after being made aware of the Korean law governing minors’ organ donation, and the severity grade of donors’ and recipients’ complications following transplantation.

(2) Respondents’ perception and attitude toward the donation and reception of minors’ organs was further investigated after basic information and additional explanations were provided: The survey in which respondents were educated using structured material was divided into basic and additional explanations. Adults were informed of the overall outcomes and complications associated with the living donation before being asked if they would accept a liver or kidney graft from a family member or minor (Questions 13, 20). Following that, the same questions (Questions 16, 23) were asked after the lack of data, the uncertainty of outcomes associated with living liver donation in minors despite their long-life expectancy, and long-term complications in living kidney donors associated with living with one kidney had been explained to them. Minors among the respondents were also given the same explanations and asked whether they would be willing to donate their liver or kidney to their parents or siblings (Questions 11–12, Questions 18–19, Questions 14–15, and Questions 21–22). Finally, whether providing additional structured explanations influenced respondents’ attitudes was also determined. Questions from 17 to 24 were included to ascertain why respondents altered their decisions after receiving additional explanations.

(3) Post-survey stage: After the survey stage, Question 27, the same question as Question 1, was asked to investigate whether there was any change in respondents’ attitudes toward minors’ organ transplantation following the questionnaire with additional information.

Full text: Click here
Publication 2023
Adult Donors Family Member Kidney Kidney Transplantation Koreans Liver Living Donors Organ Transplantation Parent Pediatricians Sibling Surgeons Transplantation Youth
Inclusion criteria for selected studies were: (1) Studies written in English language; and (2) Studies analyzing postoperative hypophosphatemia as a prognostic factor for PHLF, overall postoperative morbidity and liver regeneration (patients after different types of liver resections, including living-donor liver donation). Exclusion criteria were as follows: (1) Abstracts, case reports, editorials, letters, systematic reviews and meta-analyses; (2) Studies with incomplete data for further analysis (studies with no reported postoperative complications or phosphorus, studies analyzing postoperative hypophosphatemia in liver transplant recipients); (3) Duplicate studies; and (4) Studies in languages other than English.
Publication 2023
Hepatectomy Hypophosphatemia Liver Liver Regeneration Living Donors Patients Phosphorus Postoperative Complications Prognostic Factors Transplant Recipients
Living kidney donors were categorized based on their early follow-up status.
Early guideline-concordant follow-up care was defined as evidence of annual
outpatient physician visits, serum creatinine measurements, and albuminuria
measurements at both the first- and second-year anniversary date (±6 months). We
did not consider physician visits or laboratory values in the first 6 months
after donation, as these are usually related to postoperative monitoring.
Urinalysis, urine protein-creatinine ratio measurement, or urine
albumin-creatinine ratio measurement qualified as albuminuria measurements in
any given year.
Publication 2023
Creatinine Follow-Up Care Kidney Living Donors Physicians Proteins Serum Urinalysis Urine

Top products related to «Living Donors»

Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
Sourced in United States, China, United Kingdom
The Human Genome U133 Plus 2.0 Array is a high-density oligonucleotide microarray designed to analyze the expression of over 47,000 transcripts and variants from the human genome. It provides comprehensive coverage of the human transcriptome and is suitable for a wide range of gene expression studies.
Sourced in Switzerland, United States, Canada
Simulect is a laboratory equipment product manufactured by Novartis. It is designed for use in scientific research and clinical applications.
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
Sourced in Sweden, United States, United Kingdom, Germany, Canada, Belgium, Italy, Australia, Austria, France, Japan, Singapore, Denmark
Ficoll-Paque is a density gradient medium used for the isolation and purification of cells, such as mononuclear cells, from whole blood or other biological samples. It is designed to separate different cell types based on their density differences during centrifugation.
CryoStor CS10 is a cryopreservation medium developed by BioLife Solutions. It is designed to protect cells and tissues during the freezing and thawing process. The medium contains a defined composition of ingredients that help maintain cell viability and functionality.
Sourced in United States
The BI-200SM goniometer is a versatile instrument used for the measurement of angular-dependent properties of materials. It provides precise and reliable data on the scattering characteristics of samples, such as light, X-rays, or neutrons. The core function of the BI-200SM is to accurately measure the angular dependence of the scattered intensity from a sample.
Sourced in Canada, France, United Kingdom
CryoStor is a cryopreservation medium designed to preserve and protect cells, tissues, and other biological samples during freezing and storage. It is formulated to maintain cell viability and functionality after thawing.
Sourced in United States, United Kingdom, Japan, Germany, Austria, Belgium, France, Denmark
SPSS 24.0 is a statistical software package developed by IBM. It provides data management, analysis, and reporting capabilities. The software is designed to handle a wide range of data types and is commonly used for social science research, market research, and business analytics.

More about "Living Donors"

Living donors are individuals who selflessly provide organs or tissues for transplantation, a life-saving and life-enhancing act.
PubCompare.ai's innovative platform empowers living donor research by streamlining the process of identifying the best protocols from literature, preprints, and patents.
Its intuitive tools leverage AI-driven comparisons to help researchers easily locate and optimize the ideal protocols and products for their needs.
Living donor research is a critical field of medicine that relies on efficient and effective processes.
PubCompare.ai's platform utilizes advanced technology, including AI-driven comparisons, to assist researchers in identifying the best protocols and products for their living donor studies.
This can include leveraging insights from related fields, such as the use of Penicillin, Streptomycin, and the Human Genome U133 Plus 2.0 Array in biomedical research, as well as techniques like Ficoll-Paque separation and cryopreservation with CryoStor CS10 medium.
By streamlining the research process and providing intuitive tools, PubCompare.ai helps living donor researchers optimize their protocols and products, ultimately contributing to advancements in this important area of medicine.
Whether you're studying the use of Simulect in transplant recipients or analyzing data with SPSS 24.0, PubCompare.ai's platform can enhance your living donor research and lead to improved outcomes for donors and recipients alike.
With its innovative approach, PubCompare.ai empowers researchers to discover the best protocols and make a real difference in the lives of those in need of transplantation.